特一药业(002728) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 reached ¥304,157,421.18, representing a 56.50% increase compared to ¥194,348,090.18 in the same period last year[3] - Net profit attributable to shareholders was ¥105,470,920.94, a significant increase of 130.96% from ¥45,666,688.38 year-on-year[3] - Basic earnings per share rose to ¥0.46, up 119.05% from ¥0.21 in the previous year[3] - Operating profit for the quarter was CNY 127,043,924.70, compared to CNY 54,538,015.75 in Q1 2022, marking an increase of 133.3%[15] - The company’s total comprehensive income for the quarter was CNY 105,470,920.94, up from CNY 45,666,688.38 in the same period last year, indicating a growth of 131.3%[16] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,498,981,899.98, a decrease of 1.83% from ¥2,545,604,654.93 at the end of the previous year[3] - Cash and cash equivalents at the end of Q1 2023 totaled ¥700,881,200.19, down from ¥739,660,362.06 at the beginning of the year[10] - Total assets as of March 31, 2023, were ¥2,498,981,899.98, a decrease from ¥2,545,604,654.93 at the beginning of the year[12] - Total liabilities decreased to ¥989,721,619.89 from ¥1,142,465,215.38 at the start of the year[12] - The company's equity attributable to shareholders increased to ¥1,509,260,280.09, up from ¥1,403,139,439.55 at the beginning of the year[12] Cash Flow - The company reported a net cash flow from operating activities of ¥26,912,422.14, slightly up by 1.02% from ¥26,640,062.41[3] - Cash flow from operating activities generated a net inflow of CNY 26,912,422.14, slightly up from CNY 26,640,062.41 in the previous year[16] - The net cash outflow from investing activities was CNY -19,235,255.51, compared to CNY -63,112,412.77 in the same period last year[17] - Cash inflow from financing activities totaled CNY 63,918,749.00, a decrease from CNY 229,000,000.00 in Q1 2022[17] Costs and Expenses - Total operating costs for Q1 2023 were ¥180,960,104.90, up 29.2% from ¥140,109,023.79 in Q1 2022[14] - Research and development expenses increased to ¥10,182,147.51, reflecting a rise of 17.7% from ¥8,650,287.50 in the previous year[14] - The company incurred a tax expense of CNY 21,553,510.03, compared to CNY 8,718,235.87 in the previous year, reflecting a growth of 147.0%[15] Market and Growth Strategy - The increase in revenue was primarily driven by a significant rise in pharmaceutical sales, contributing to a gross profit margin increase[5] - The company plans to continue expanding its market presence and investing in new product development to sustain growth[5] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[11] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 67,464, with the largest shareholder holding 31.16% of the shares[7]